Yifan Pharmaceutical Co., Ltd.

Equities

002019

CNE000001K65

Pharmaceuticals

End-of-day quote Shenzhen S.E. 06:00:00 2024-06-06 pm EDT 5-day change 1st Jan Change
13.01 CNY -0.23% Intraday chart for Yifan Pharmaceutical Co., Ltd. -2.62% -11.98%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Yifan Pharmaceutical Gets Nod to Register Phloroglucinol Injection MT
Yifan Pharmaceutical Unit Gets Authorization to Sell Circulation Supplement in Singapore MT
Yifan Unit's Allergy Drug Passes China Regulatory Test, Stock Price Jumps MT
Yifan Pharmaceutical's Unit Gets Nod to Register Nimodipine Injection MT
Three Drugs of Yifan Pharmaceutical's Unit Placed in China's Centralized Procurement MT
Yifan Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Yifan Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Yifan Pharmaceutical Gets EU Nod to Sell Ryzneuta Drug MT
Tranche Update on Yifan Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on August 31, 2023. CI
Yifan Pharmaceutical Co., Ltd.'s Equity Buyback announced on August 31, 2023, has closed with 2,412,900 shares, representing 0.2% for CNY 38 million. CI
Yifan Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Tranche Update on Yifan Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on August 31, 2023. CI
Yifan Pharmaceutical Co., Ltd. announces an Equity Buyback for CNY 50 million worth of its shares. CI
Yifan Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Yifan Pharmaceutical Co., Ltd. authorizes a Buyback Plan. CI
Yifan Pharma CFO Resigns; Successor Named MT
Yifan Pharma Registers Leukemia Drug in China MT
Yifan Pharmaceutical Registers Coronary Syndrome Treatment MT
Yifan Pharmaceutical Unit Registers Cancer Treatment in China MT
Yifan Pharmaceutical Registers Dopamine Hydrochloride MT
Yifan Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Yifan Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Yifan Pharma Gets Nod to Register Another Hypotension Drug MT
Yifan Pharmaceutical Registers Blood Pressure Control Drug MT
Yifan Pharma Registers Seizure Drug in China MT
Chart Yifan Pharmaceutical Co., Ltd.
More charts
Yifan Pharmaceutical Co Ltd is a China-based company mainly engaged in the research and development, production, sales and pharmaceutical promotion services of pharmaceutical products, active pharmaceutical ingredient and polymer materials. The Company conducts business through two segments. The Pharmaceutical Products segment mainly produces Chinese patent medicines, chemical drugs and biological drugs. Its products include Xiaoer Qingqiao granules, Piminxiao capsules, lactulose oral solution and granulocyte colony stimulating factor. The Pharmaceutical Raw Materials and Polymers segment mainly produces active pharmaceutical ingredient, and its products are mainly vitamin B5 and pro-B5. The Company mainly conducts business in domestic and foreign markets.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
13.01 CNY
Average target price
19 CNY
Spread / Average Target
+46.04%
Consensus

Annual profits - Rate of surprise

  1. Stock Market
  2. Equities
  3. 002019 Stock
  4. News Yifan Pharmaceutical Co., Ltd.
  5. Yifan Pharmaceutical Unit Gets Authorization to Sell Circulation Supplement in Singapore